U.S. Physical Therapy (NYSE:USPH) had a strong opening on May 10th, starting at $114.29 and reaching an impressive market capitalization of $1.49 billion. The company has demonstrated steady growth, with a one-year low of $73.30 and a one-year high of $131.50.
The firm’s current ratio of 1.30 and quick ratio of 1.30 indicate that the company is in good financial health, despite its debt-to-equity ratio of 0.57 and PEG ratio of 4.36 indicating slower growth compared to its peers.
Several analysts have recently upgraded their ratings for the stock, including StockNews.com upgrading U.S Physical Therapy from a “sell” rating to a “hold,” Barrington Research boosting its price objective from $110 to $116, and TheStreet upgrading the stock from a “c+” rating to a “b-.”
In terms of insider trading, CFO Carey P. Hendrickson sold 471 shares of U.S Physical Therapy stock in March at an average price of $95.80 per share, while EVP Richard Binstein sold 911 shares in March at an average price of $100.78 per share.
U.S Physical Therapy’s recent earnings report was also quite positive, with the company reporting earnings per share (EPS) of $0.59 for the quarter ending on May 3rd, surpassing analysts’ consensus estimates by $0.07 per share.
The company’s revenue was up by 12.8% compared to the same quarter last year, indicating strong growth potential for U.S Physical Therapy in the near future.
Overall, U.S Physical Therapy has demonstrated its ability to generate consistent revenue and maintain strong financial health despite challenges faced due to its debt-to-equity ratios and PEG ratio being lower than industry averages.
With recent upgrades by several analysts, positive insider trading, and a strong earnings report, the future looks bright for U.S Physical Therapy. Investors should keep an eye on this stock going forward.
US Physical Therapy, Inc. Faces Decrease in Q2 2023 EPS Estimates, Hedge Funds Modify Holdings
On May 10, 2023, U.S. Physical Therapy, Inc. (NYSE:USPH) made headlines as William Blair analysts decreased their Q2 2023 EPS estimates for the company in a research note issued on Monday, May 8th. According to William Blair analyst M. Larew’s revised projections, the company would post earnings per share of $0.71 for the quarter – down from the previous estimate of $0.82. The consensus estimate for U.S. Physical Therapy’s current full-year earnings is pegged at $2.62 per share.
Furthermore, William Blair also issued estimates for U.S. Physical Therapy’s FY2023 earnings at $2.61 EPS, Q2 2024 earnings at $0.85 EPS and FY2024 earnings at $3.37 EPS.
In light of these numbers, it is worth noting that several hedge funds have recently made modifications to their holdings in the business. For instance, JPMorgan Chase & Co.’s holdings in shares of U.S. Physical Therapy rose by 314.9% during the first quarter; Raymond James & Associates bought a new position in shares of the company during the same period valued at about $279,000; Citigroup Inc.’s holdings increased by 3.2%; MetLife Investment Management LLC’s holdings skyrocketed by 61.1%, and Rhumbline Advisers’ stake bumped up by 44.9%.
To provide some context on U.S Phycial Therapy, it’s vital to understand that institutional investors and hedge funds own a significant percentage (98%) of its stock.
It remains to be seen how much impact William Blair’s analysis will have on USPH stock going forward and if there will be any changes implemented in response to this emerging scenario.
As always when dealing with such intricate economic systems, investors should remain informed and keep themselves updated on future developments in a fast-paced financial environment.